Switch theme
Sign up to access all valuation multiples
Sunmax Biotechnology Co Ltd is a biomedical company in Taiwan. It is engaged in the development, manufacturing, and commercialization of Sunmax medical devices and bio-surgical products. Additionally, it also researches, develops, manufactures and sales biomedical material grade collagen and related products. The company's products include medical products, biomedical materials, and porcine collagen skin care products.
2001
109
LTM Revenue n/a
LTM EBITDA n/a
$621M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sunmax Biotechnology has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Sunmax Biotechnology achieved revenue of $28.7M and an EBITDA of $27.5M.
Sunmax Biotechnology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sunmax Biotechnology valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $51.0M | $28.7M | XXX | XXX | XXX |
| Gross Profit | $36.0M | $42.4M | XXX | XXX | XXX |
| Gross Margin | 71% | 148% | XXX | XXX | XXX |
| EBITDA | $29.7M | $27.5M | XXX | XXX | XXX |
| EBITDA Margin | 58% | 96% | XXX | XXX | XXX |
| Net Profit | $16.1M | $18.9M | XXX | XXX | XXX |
| Net Margin | 32% | 66% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Sunmax Biotechnology's stock price is TWD 383 (or $12).
Sunmax Biotechnology has current market cap of TWD 20.8B (or $629M), and EV of TWD 20.6B (or $621M).
See Sunmax Biotechnology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $621M | $629M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Sunmax Biotechnology has market cap of $629M and EV of $621M.
Sunmax Biotechnology's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Sunmax Biotechnology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Sunmax Biotechnology and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $621M | XXX | XXX | XXX |
| EV/Revenue | 21.7x | XXX | XXX | XXX |
| EV/EBITDA | 22.6x | XXX | XXX | XXX |
| P/E | 30.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 57.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSunmax Biotechnology's NTM/LTM revenue growth is n/a
Sunmax Biotechnology's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Sunmax Biotechnology's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Sunmax Biotechnology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Sunmax Biotechnology and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -44% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 96% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -8% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 10% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 21% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sunmax Biotechnology acquired XXX companies to date.
Last acquisition by Sunmax Biotechnology was XXXXXXXX, XXXXX XXXXX XXXXXX . Sunmax Biotechnology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Sunmax Biotechnology founded? | Sunmax Biotechnology was founded in 2001. |
| Where is Sunmax Biotechnology headquartered? | Sunmax Biotechnology is headquartered in Taiwan. |
| How many employees does Sunmax Biotechnology have? | As of today, Sunmax Biotechnology has 109 employees. |
| Is Sunmax Biotechnology publicy listed? | Yes, Sunmax Biotechnology is a public company listed on ROCO. |
| What is the stock symbol of Sunmax Biotechnology? | Sunmax Biotechnology trades under 4728 ticker. |
| When did Sunmax Biotechnology go public? | Sunmax Biotechnology went public in 2012. |
| Who are competitors of Sunmax Biotechnology? | Similar companies to Sunmax Biotechnology include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Sunmax Biotechnology? | Sunmax Biotechnology's current market cap is $629M |
| What is the current revenue growth of Sunmax Biotechnology? | Sunmax Biotechnology revenue growth between 2023 and 2024 was -44%. |
| Is Sunmax Biotechnology profitable? | Yes, Sunmax Biotechnology is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
